What is Noble Financial's Forecast for GYRE Q3 Earnings?

Key Points

• Noble Financial analysts project that Gyre Therapeutics will achieve earnings per share of $0.03 in Q3 2025, with further estimates indicating $0.05 EPS for Q4 2025 and $0.51 EPS for FY2026.
• Gyre Therapeutics recently reported Q2 earnings of $0.02 EPS, missing estimates, with a revenue of $26.77 million falling short of the consensus of $30.80 million.
• The stock received a "buy" rating from HC Wainwright, with a target price set at $18.00, supported by a consensus rating of "Buy" from multiple analysts.

Gyre Therapeutics, Inc. (NASDAQ:GYRE - Free Report) - Analysts at Noble Financial issued their Q3 2025 EPS estimates for Gyre Therapeutics in a note issued to investors on Tuesday, September 9th. Noble Financial analyst R. Leboyer anticipates that the company will earn $0.03 per share for the quarter. Noble Financial also issued estimates for Gyre Therapeutics' Q4 2025 earnings at $0.05 EPS, FY2025 earnings at $0.09 EPS and FY2026 earnings at $0.51 EPS.

Separately, HC Wainwright started coverage on shares of Gyre Therapeutics in a research report on Tuesday, August 26th. They set a "buy" rating and a $18.00 price target on the stock. Two analysts have rated the stock with a Buy rating, According to MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $18.00.

Gyre Therapeutics Stock Down 3.6%

GYRE stock traded down $0.29 during mid-day trading on Thursday, hitting $7.83. 74,967 shares of the company were exchanged, compared to its average volume of 94,607. The firm has a market capitalization of $754.11 million, a P/E ratio of 783.78 and a beta of 1.86. The business has a fifty day simple moving average of $7.62 and a 200-day simple moving average of $8.57. Gyre Therapeutics has a 12-month low of $6.11 and a 12-month high of $19.00.

Gyre Therapeutics (NASDAQ:GYRE - Get Free Report) last announced its quarterly earnings data on Monday, August 11th. The company reported $0.02 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.03 by ($0.01). The firm had revenue of $26.77 million during the quarter, compared to analysts' expectations of $30.80 million. Gyre Therapeutics had a net margin of 4.08% and a return on equity of 7.67%.

Hedge Funds Weigh In On Gyre Therapeutics

Institutional investors have recently modified their holdings of the business. Bank of America Corp DE boosted its position in shares of Gyre Therapeutics by 28.8% during the 2nd quarter. Bank of America Corp DE now owns 6,277 shares of the company's stock worth $46,000 after purchasing an additional 1,402 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of Gyre Therapeutics by 84.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 6,461 shares of the company's stock worth $47,000 after buying an additional 2,961 shares in the last quarter. Wells Fargo & Company MN raised its stake in Gyre Therapeutics by 29.4% in the 4th quarter. Wells Fargo & Company MN now owns 4,016 shares of the company's stock valued at $49,000 after purchasing an additional 913 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Gyre Therapeutics by 77.8% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,413 shares of the company's stock valued at $54,000 after purchasing an additional 3,244 shares during the last quarter. Finally, Advantage Alpha Capital Partners LP increased its stake in shares of Gyre Therapeutics by 54.0% during the 1st quarter. Advantage Alpha Capital Partners LP now owns 13,663 shares of the company's stock valued at $105,000 after acquiring an additional 4,790 shares during the last quarter. 23.99% of the stock is owned by institutional investors and hedge funds.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.